Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.58 |
| ▸ | DRD2 | P14416 | 10/20 | 0.56 |
| ▸ | DRD3 | P35462 | 8/20 | 0.56 |
| ▸ | HTR1A | P08908 | 6/20 | 0.56 |
| ▸ | HTR2A | P28223 | 5/20 | 0.56 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.56 |
| ▸ | DRD5 | P21918 | 5/20 | 0.55 |
| ▸ | DRD1 | P21728 | 3/20 | 0.55 |
| ▸ | DRD4 | P21917 | 3/20 | 0.52 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18754269 | 0.85 | KDM4E (0.75) | KDM4EGAASIGMAR1DRD2DRD3 | |
| SCHEMBL7055358 | 0.84 | KCNH2 (0.51) | KDM4EGAASIGMAR1DRD2DRD3 | |
| SCHEMBL6366461 | 0.84 | HTR1A (0.55) | KDM4EGAASIGMAR1DRD2DRD3 | |
| SCHEMBL6367416 | 0.84 | SLC6A2 (0.52) | KDM4EGAADRD2DRD3HTR1A | |
| SCHEMBL5179759 | 0.80 | KDM4E (0.69) | KDM4EGAASIGMAR1DRD2DRD3 | |
| SCHEMBL5185979 | 0.80 | SLC6A2 (0.51) | KDM4EGAADRD2DRD3HTR1A | |
| SCHEMBL9393977 | 0.79 | KDM4E (0.67) | KDM4EGAASIGMAR1DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL11622828 | 0.79 | KDM4E (0.67) | KDM4EGAASIGMAR1DRD2DRD3 | |
| SCHEMBL14459608 | 0.79 | KDM4E (0.88) | KDM4EGAASIGMAR1DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL11637430 | 0.79 | KDM4E (0.67) | KDM4EGAASIGMAR1DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2870140-B1 | TETRAHYDROQUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | LUPIN LTD (IN) | 2016-07-27 | — | — | EP | disclosed |
| EP-2870140-B1 | TETRAHYDROQUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | LUPIN LTD (IN) | 2016-07-27 | — | — | EP | disclosed |
| US-9359367-B2 | Tetrahydroquinazolinone derivatives as PARP inhibitors | LUPIN LIMITED (IN) | 2016-06-07 | — | — | US | disclosed |
| US-9359367-B2 | Tetrahydroquinazolinone derivatives as PARP inhibitors | LUPIN LIMITED (IN) | 2016-06-07 | — | — | US | disclosed |
| US-20150152118-A1 | Tetrahydroquinazolinone Derivatives as PARP Inhibitors | LUPIN LIMITED (IN) | 2015-06-04 | — | — | US | disclosed |
| US-20150152118-A1 | Tetrahydroquinazolinone Derivatives as PARP Inhibitors | LUPIN LIMITED (IN) | 2015-06-04 | — | — | US | disclosed |
| EP-2870140-A1 | TETRAHYDROQUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | Lupin Limited (IN) | 2015-05-13 | — | — | EP | disclosed |
| WO-2014009872-A1 | TETRAHYDROQUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | LUPIN LIMITED (IN) | 2014-01-16 | — | — | WO | disclosed |
| WO-2014009872-A1 | TETRAHYDROQUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | LUPIN LIMITED (IN) | 2014-01-16 | — | — | WO | disclosed |
| US-20050080096-A1 | Condensed heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-04-14 | — | — | US | disclosed |
| EP-1469854-A1 | CONDENSED HETEROCYCLIC COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-10-27 | — | — | EP | disclosed |
| WO-2003063874-A1 | CONDENSED HETEROCYCLIC COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080096-A1 | Condensed heterocyclic compounds | PARP1, PARP2, PARP3 | KDM4E 1190/4885GAA 2062/4885SIGMAR1 3797/4885 |
| US-20150152118-A1 | Tetrahydroquinazolinone Derivatives as PARP Inhibitors | PARP1, PARP11, PARP3 | KDM4E 888/4885GAA 3529/4885SIGMAR1 4110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.